{"id":"W2059370935","doi":"10.1038/bjc.2013.523","title":"Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer","year":2013,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"GLS Industries (Canada)","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"FOLFIRI; Aflibercept; Medicine; Internal medicine; Oxaliplatin; Population; Irinotecan; Placebo; Colorectal cancer; Survival analysis; Oncology; Regimen; Surgery; Bevacizumab; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004174679,0.0003475697,0.0007523664,0.0003106926,0.0001030021,0.0005270279,0.0002334548,0.0003081194,0.000916215],"category_scores_gemma":[0.006095696,0.00008511073,0.001084929,0.0002562174,0.0002954333,0.0005007283,0.0003084095,0.000866918,0.00009142623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005738786,"about_ca_system_score_gemma":0.0003549862,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003978964,"about_ca_topic_score_gemma":0.0005348435,"domain_scores_codex":[0.9992157,0.000467141,0.00004829615,0.0001056911,0.0001049897,0.00005821878],"domain_scores_gemma":[0.9975496,0.001584302,0.0005474934,0.0001351544,0.00007157803,0.0001118131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4291699,0.002371747,0.1604887,0.001619817,0.007031819,0.0001966083,0.0005966675,0.03513947,0.0184124,0.001008074,0.001602015,0.3423628],"study_design_scores_gemma":[0.0325533,0.2924167,0.6076531,0.0003073129,0.00872345,0.0007889568,0.0003046897,0.03480015,0.01449925,0.003663647,0.004178318,0.0001111314],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943989,0.002990913,0.001237087,0.0002692967,0.00002675875,0.00006646841,0.0001856967,0.00003608556,0.0007887991],"genre_scores_gemma":[0.9991907,0.0002215018,0.00027233,0.00005254825,0.00001713239,0.00003278991,0.0001177872,0.0000027693,0.00009240508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004174679,"threshold_uncertainty_score":0.0220781,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01176929790389344,"score_gpt":0.2616818364557736,"score_spread":0.2499125385518802,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}